HIV does not directly cause cancer the way a carcinogen damages DNA, but it dramatically increases the risk of developing certain cancers. People living with HIV are nearly four times more likely to develop cancer overall compared to the general population. This elevated risk comes from two main pathways: HIV weakens the immune system so it can no longer detect and destroy abnormal cells, and it creates chronic inflammation that actively promotes tumor growth.
How HIV Creates Conditions for Cancer
HIV attacks immune cells, specifically the CD4 cells that coordinate your body’s defense against infections and abnormal cell growth. As these cells decline, the immune system loses its ability to perform one of its lesser-known jobs: surveilling the body for cells that are turning cancerous and eliminating them before they multiply. This process, sometimes called immune surveillance, is one of the body’s most important built-in protections against tumors.
At the same time, HIV triggers a state of persistent, low-grade inflammation that continues even when the virus is well controlled with treatment. This chronic inflammation generates reactive molecules that can damage DNA and proteins in healthy cells, nudging them toward becoming cancerous. It also releases chemical signals that help already-transformed cells grow and spread. Over time, the inflammation itself exhausts the immune system further, creating a feedback loop: more inflammation leads to weaker immune defenses, which allows more abnormal cells to survive unchecked.
A 2024 study of 2.8 million people living with HIV in South Africa found that higher levels of virus in the blood correlated with increased cancer risk for several types, even after accounting for immune cell counts. For Kaposi sarcoma specifically, each tenfold increase in viral load raised the risk by 38%. This suggests that the virus contributes to cancer through mechanisms beyond simple immune suppression, likely through the inflammatory environment it maintains.
AIDS-Defining Cancers
Three cancers are so closely tied to advanced HIV infection that a diagnosis of any one of them qualifies as an AIDS-defining condition, according to the CDC:
- Kaposi sarcoma appears as purple, red, or brown skin lesions and can also affect the mouth, lungs, and digestive tract. It is caused by a virus called HHV-8, which normally the immune system keeps in check. When HIV suppresses immune function, HHV-8 replicates freely and drives the growth of abnormal blood vessel cells. People with low CD4 counts and uncontrolled HIV are at highest risk.
- Non-Hodgkin lymphoma is a cancer of the immune system itself. People with HIV face a risk roughly 25 times higher than the general population. The most aggressive forms, including Burkitt lymphoma and a subtype called immunoblastic diffuse large B-cell lymphoma, make up the majority of cases. About 15 to 30 percent of HIV-associated non-Hodgkin lymphomas originate in the brain.
- Invasive cervical cancer is driven by persistent infection with HPV. HIV weakens the immune response that would normally clear HPV, allowing it to linger and cause progressive cell changes in the cervix. The risk is about four times higher than in the general population.
Non-AIDS-Defining Cancers
As HIV treatment has improved and people are living longer, a second category of cancers has become increasingly important. These are cancers that occur more frequently in people with HIV but are not classified as AIDS-defining conditions. Lung cancer is the most common, followed by Hodgkin lymphoma and breast cancer.
Many of these cancers are linked to viral co-infections that HIV allows to flourish. Liver cancer is driven by hepatitis B and C, which are common co-infections in people with HIV. Anal, throat, and vulvar cancers are tied to HPV. Hodgkin lymphoma is associated with Epstein-Barr virus. In each case, the pattern is similar: a virus that causes cancer is normally kept under control by a healthy immune system, but HIV tips the balance.
Some non-AIDS-defining cancers have no known viral cause. Population-level data show that people with HIV face elevated risks for oral cancer (about 3.3 times higher), kidney and bladder cancer (4.8 times), liver cancer (3.75 times), colorectal cancer (2.2 times), and certain skin cancers (3.4 times) compared to the general population. The reasons for these increases likely involve chronic inflammation, higher rates of smoking and alcohol use in this population, and possibly direct effects of HIV on cellular processes.
How Treatment Changes the Picture
Starting antiretroviral therapy early makes a substantial difference for virus-related cancers. A large North American cohort study found that people who began treatment earlier had a 64% lower risk of AIDS-defining cancers, a 59% lower risk of any virus-related cancer, and a 30% lower risk of cancer overall compared to those who delayed treatment. For Kaposi sarcoma specifically, earlier treatment cut the risk by 75%. For non-Hodgkin lymphoma, the reduction was 78%.
The impact is visible at a population level too. Before effective HIV treatment existed, the most aggressive form of diffuse large B-cell lymphoma accounted for 38% of HIV-associated lymphomas. After widespread treatment became available, that proportion dropped to 19%. Primary brain lymphoma similarly fell from 28% to 17% of cases.
There is an important caveat, though. Earlier treatment did not significantly reduce the risk of cancers without a known viral cause, such as lung and prostate cancer. By 15 years, the cumulative incidence of virus-related cancers was 2.6% with early treatment versus 6.9% with delayed treatment, a meaningful gap. But for cancers unrelated to viral co-infections, immune recovery alone does not appear to offer much protection. This means that even with well-controlled HIV, standard cancer prevention strategies like not smoking, limiting alcohol, and keeping up with screening remain critical.
Why Viral Load Matters
Keeping HIV viral load undetectable does more than protect the immune system. The South African study of 2.8 million people found that higher viral loads independently increased the risk of several cancers even after controlling for CD4 count. Each unit increase in viral load (on a logarithmic scale) raised the risk of Kaposi sarcoma by 38%, leukemia by 28%, non-Hodgkin lymphoma by 24%, and colorectal cancer by 11%. This held true regardless of how many immune cells a person had, suggesting that the virus itself, through the inflammatory environment it creates, plays a direct role in promoting cancer development.
The practical takeaway is straightforward: consistent, uninterrupted treatment that keeps viral load suppressed is one of the most effective ways to lower cancer risk. Treatment gaps that allow the virus to rebound may reactivate the inflammatory pathways that encourage tumor growth, even if CD4 counts remain relatively stable.
Cancers With the Highest Relative Risk
To put the numbers in perspective, here are the cancers with the most dramatically elevated risk in people living with HIV compared to the general population:
- Non-Hodgkin lymphoma: approximately 25 times higher risk
- Lymphoma overall: approximately 20 times higher risk
- Lung and respiratory cancers: approximately 20 times higher risk
- Kidney and bladder cancers: approximately 5 times higher risk
- Cervical cancer: approximately 4 times higher risk
- Breast cancer: approximately 4 times higher risk
- Liver cancer: approximately 3.75 times higher risk
- Oral cancer: approximately 3.3 times higher risk
- Colorectal cancer: approximately 2.2 times higher risk
These numbers represent population averages. Individual risk varies widely depending on viral load control, CD4 count, co-infections, smoking status, and other lifestyle factors. A person with well-controlled HIV, no viral co-infections, and no tobacco use will have a very different risk profile than someone with uncontrolled virus and active hepatitis.